Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Using physiologically-based pharmacokinetic models to incorporate chemical and non-chemical stressors into cumulative risk assessment: a case study of pesticide exposures.

Wason SC, Smith TJ, Perry MJ, Levy JI.

Int J Environ Res Public Health. 2012 May;9(5):1971-83. doi: 10.3390/ijerph9051971. Epub 2012 May 22.

2.

Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion.

Foxenberg RJ, Ellison CA, Knaak JB, Ma C, Olson JR.

Toxicology. 2011 Jul 11;285(1-2):57-66. doi: 10.1016/j.tox.2011.04.002. Epub 2011 Apr 13.

PMID:
21514354
3.

Development of a source-to-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos.

Hinderliter PM, Price PS, Bartels MJ, Timchalk C, Poet TS.

Regul Toxicol Pharmacol. 2011 Oct;61(1):82-92. doi: 10.1016/j.yrtph.2011.06.004. Epub 2011 Jun 22.

PMID:
21722690
4.
5.

A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans.

Timchalk C, Nolan RJ, Mendrala AL, Dittenber DA, Brzak KA, Mattsson JL.

Toxicol Sci. 2002 Mar;66(1):34-53.

PMID:
11861971
6.

The implications of using a physiologically based pharmacokinetic (PBPK) model for pesticide risk assessment.

Lu C, Holbrook CM, Andres LM.

Environ Health Perspect. 2010 Jan;118(1):125-30. doi: 10.1289/ehp.0901144.

7.
8.

Appraisal of risks from nonoccupational exposure to chlorpyrifos.

Cochran RC.

Regul Toxicol Pharmacol. 2002 Feb;35(1):105-21. Review.

PMID:
11846640
9.

Modeling exposures to organophosphates and pyrethroids for children living in an urban low-income environment.

Wason SC, Julien R, Perry MJ, Smith TJ, Levy JI.

Environ Res. 2013 Jul;124:13-22. doi: 10.1016/j.envres.2012.08.009. Epub 2013 May 10.

PMID:
23664738
10.

Parameters for pyrethroid insecticide QSAR and PBPK/PD models for human risk assessment.

Knaak JB, Dary CC, Zhang X, Gerlach RW, Tornero-Velez R, Chang DT, Goldsmith R, Blancato JN.

Rev Environ Contam Toxicol. 2012;219:1-114. doi: 10.1007/978-1-4614-3281-4_1. Review.

PMID:
22610175
11.

Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy.

Garabrant DH, Aylward LL, Berent S, Chen Q, Timchalk C, Burns CJ, Hays SM, Albers JW.

J Expo Sci Environ Epidemiol. 2009 Nov;19(7):634-42. doi: 10.1038/jes.2008.51. Epub 2008 Aug 20.

PMID:
18716607
12.

Binary combinations of organophosphorus and synthetic pyrethroids are more potent acetylcholinesterase inhibitors than organophosphorus and carbamate mixtures: An in vitro assessment.

Arora S, Balotra S, Pandey G, Kumar A.

Toxicol Lett. 2017 Feb 15;268:8-16. doi: 10.1016/j.toxlet.2016.12.009. Epub 2016 Dec 14.

PMID:
27988393
13.

Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues.

Price PS, Schnelle KD, Cleveland CB, Bartels MJ, Hinderliter PM, Timchalk C, Poet TS.

Regul Toxicol Pharmacol. 2011 Oct;61(1):23-31. doi: 10.1016/j.yrtph.2011.05.009. Epub 2011 May 30.

PMID:
21651950
14.

Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.

Yoon M, Kedderis GL, Yan GZ, Clewell HJ 3rd.

Toxicology. 2015 Jun 5;332:52-66. doi: 10.1016/j.tox.2014.05.006. Epub 2014 May 24.

PMID:
24863738
15.

Cumulative organophosphate pesticide exposure and risk assessment among pregnant women living in an agricultural community: a case study from the CHAMACOS cohort.

Castorina R, Bradman A, McKone TE, Barr DB, Harnly ME, Eskenazi B.

Environ Health Perspect. 2003 Oct;111(13):1640-8.

17.

Pharmacokinetics and pharmacodynamics of chlorpyrifos in adult male Long-Evans rats following repeated subcutaneous exposure to chlorpyrifos.

Ellison CA, Smith JN, Lein PJ, Olson JR.

Toxicology. 2011 Sep 5;287(1-3):137-44. doi: 10.1016/j.tox.2011.06.010. Epub 2011 Jun 17.

18.

Chlorpyrifos PBPK/PD model for multiple routes of exposure.

Poet TS, Timchalk C, Hotchkiss JA, Bartels MJ.

Xenobiotica. 2014 Oct;44(10):868-81. doi: 10.3109/00498254.2014.918295. Epub 2014 May 19.

PMID:
24839995
19.

A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation.

Smith JN, Hinderliter PM, Timchalk C, Bartels MJ, Poet TS.

Regul Toxicol Pharmacol. 2014 Aug;69(3):580-97. doi: 10.1016/j.yrtph.2013.10.005. Epub 2013 Nov 4.

PMID:
24200834
20.

Derivation of human Biomonitoring Guidance Values for chlorpyrifos using a physiologically based pharmacokinetic and pharmacodynamic model of cholinesterase inhibition.

Arnold SM, Morriss A, Velovitch J, Juberg D, Burns CJ, Bartels M, Aggarwal M, Poet T, Hays S, Price P.

Regul Toxicol Pharmacol. 2015 Mar;71(2):235-43. doi: 10.1016/j.yrtph.2014.12.013. Epub 2014 Dec 25.

Supplemental Content

Support Center